Main Article Content
Abstract
Lilium Candium (Family liliaceae) commonly known as Madonna lilies is a vigorously growing in India. In the present study a pharmacognostic evaluation of the leaves was undertaken. In addition to the evaluation of physicochemical characteristics; preliminary Phytochemical parameters and pharmacological activities of aqueous extracts has been carried out. The aim of the present study was carried out with the objective of phytochemical screening and to evaluate the hepatoprotective activity of aqueous extract of L.candium.
Liver is the largest organ in the body which serves as a gland also. It plays an important role in the maintenance of internal environment through its multiple and diverse functions. Any damage to the liver or impairment of its functions leads to injurious effects. Liver diseases (like jaundice) are the common ailments affecting mankind, though no remedy is available in allopathic at present. In the recent past years many medicinal plants are screened for their hepatoprotective activity and quite a few of them are already successful in entering the market, Hence the present study is planned to find out the hepatoprotective activity of Lilium Candium using drug induced hepatotoxicity models like Paracetamol, CCL4 and Acetamenophenon induced methods .
The rats were divided into five groups with six rats in each for three models. Group I (Control) served as normal and received the vehicle alone (Sterile distilled water, 10 ml/kg, p.o.) for 5 days. Group II (Toxin control) animals on the 3rd and 4th day. Group III and IV were treated with LCM at a dose level of 400 mg/kg and 600 mg/kg body weight p.o. per day respectively for 5 days and on the 3rd and 4th day with hepatotoxic drugs was given 1 h after the treatment of the extract. Group V (Standard) was treated with standard drug silymarin (100 mg/kg p.o.) for 5 days and on the 3rd and 4th day hepatotoxic drugs was given 1h after the treatment of the drug. The animals were sacrificed 48 h after the last injection of hepatotoxic drugs under mild ether anesthesia. The blood was collected and allowed to stand for 30 min at 37°C and then centrifuged to separate the serum to estimate various biochemical parameters.
In hepatoprotective studies, the induced Diclofenac, CCL4 and Acetamenophenon toxicity elevated levels of serum marker enzymes ALT, AST, ALP and the level of BUN along with the decrease in total protein and albumin levels. It also increased the relative liver weight and decreased the level of liver total protein and GSH. The activity of catalase and GPx significantly decreased in diclofenac intoxicated animals. The pre-treatment of methanol extract of Lilium candidum at dose levels of 400 and 600 mg/kg had restored the ALT, AST, ALP and BUN levels towards normalization and the effects were comparable with standard drug (Silymarin 100 mg/kg). The total protein, albumin, GSH levels and catalase, GPx activity increased significantly in the animals received pre-treatment of the LCM.
The data obtained from animal experiments are expressed as mean ± SEM (standard error of mean). For statistical analysis data were subjected to analysis of variance (ANOVA) followed by Student’s t-test. Values are considered statistically significant at p < 0.01 for ANOVA and P < 0.05 for t-test.
Liver is the largest organ in the body which serves as a gland also. It plays an important role in the maintenance of internal environment through its multiple and diverse functions. Any damage to the liver or impairment of its functions leads to injurious effects. Liver diseases (like jaundice) are the common ailments affecting mankind, though no remedy is available in allopathic at present. In the recent past years many medicinal plants are screened for their hepatoprotective activity and quite a few of them are already successful in entering the market, Hence the present study is planned to find out the hepatoprotective activity of Lilium Candium using drug induced hepatotoxicity models like Paracetamol, CCL4 and Acetamenophenon induced methods .
The rats were divided into five groups with six rats in each for three models. Group I (Control) served as normal and received the vehicle alone (Sterile distilled water, 10 ml/kg, p.o.) for 5 days. Group II (Toxin control) animals on the 3rd and 4th day. Group III and IV were treated with LCM at a dose level of 400 mg/kg and 600 mg/kg body weight p.o. per day respectively for 5 days and on the 3rd and 4th day with hepatotoxic drugs was given 1 h after the treatment of the extract. Group V (Standard) was treated with standard drug silymarin (100 mg/kg p.o.) for 5 days and on the 3rd and 4th day hepatotoxic drugs was given 1h after the treatment of the drug. The animals were sacrificed 48 h after the last injection of hepatotoxic drugs under mild ether anesthesia. The blood was collected and allowed to stand for 30 min at 37°C and then centrifuged to separate the serum to estimate various biochemical parameters.
In hepatoprotective studies, the induced Diclofenac, CCL4 and Acetamenophenon toxicity elevated levels of serum marker enzymes ALT, AST, ALP and the level of BUN along with the decrease in total protein and albumin levels. It also increased the relative liver weight and decreased the level of liver total protein and GSH. The activity of catalase and GPx significantly decreased in diclofenac intoxicated animals. The pre-treatment of methanol extract of Lilium candidum at dose levels of 400 and 600 mg/kg had restored the ALT, AST, ALP and BUN levels towards normalization and the effects were comparable with standard drug (Silymarin 100 mg/kg). The total protein, albumin, GSH levels and catalase, GPx activity increased significantly in the animals received pre-treatment of the LCM.
The data obtained from animal experiments are expressed as mean ± SEM (standard error of mean). For statistical analysis data were subjected to analysis of variance (ANOVA) followed by Student’s t-test. Values are considered statistically significant at p < 0.01 for ANOVA and P < 0.05 for t-test.
Keywords
Lilium candium, hepatoprotective activity, serum, total protein, albumin, Blood Urea Nitrogen, Alkaline Phosphate, Aspartate amino trasferase, Alanine amino transferase.
Article Details
References
- 1. Shanmugasundaram P, Venkataraman S (2006). Hepatoprotective and antioxidant effects of Hygrophila auriculata (K. Schum) Heine Acanthaceae root extract. Journal of Ethnopharmacology 104: 124-128.
- 2. Saleem TSM, Chetty CM, Ramkanth S, Rajan VST, Kumar KM, Gauthaman K (2010). Hepatoprotective herbs - a review. International Journal of Research in Pharmaceutical Sciences 1: 1-5.
- 3. Kaplowitz N, Tsukamoto H (1996). Oxidative stress and liver disease. Progress in Liver Diseases 14: 131-159.
- 4. Ajith TA, Hema U, Aswathy MS (2007). Zingiber officinale Roscoe prevents acetaminophen-induced acute hepatotoxicity by enhancing hepatic antioxidant status.
- Food and Chemical Toxicology 45: 2267-2272.
- 5. Timbrell J (2001). Introduction to Toxicology. 3rd ed. Taylor and Francis, New York, pp. 57-71.
- 6. Kohen R, Nyska A (2002). Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicologic Pathology 30: 620-650.
- 7. Gupta AK, Misra N (2006). Hepatoprotective activity of aqueous ethanolic extract of Chamomile capitula in paracetamol intoxicated albino rats. American Journal of Pharmacology and Toxicology 1: 17-20.
- 8. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SPS (2008). Recent advances in plant hepatoprotectives: A chemical and biological profile of some important leads. Medicinal Research Reviews 28: 746-772.
- 9. Kohle C, Schwarz M, Bock KW (2008). Promotion of hepatocarcinogenesis in humans and animal models. Archives of Toxicology 82: 623-631.
- 10. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ (1999). Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117: 669-677.
- 11. Seki S, Kitada T, Sakaguchi H (2005). Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatology Research 33: 132-134.
- 12. Kitase A, Hino K, Furutani T, Okuda M, Gondo T, Hidaka I, Hara Y, Yamaguchi Y, Okita K (2005). In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. Journal of Gastroenterology 40: 617-624.
- 13. Albano E, Mottaran E, Occhino G, Reale E, Vidali M (2005). Role of oxidative stress in the progression of non-alcoholic steatosis. Alimentary Pharmacolcology and Therapeutics 22: 71-73.
- 14. Lee WM (2003). Acute liver failure in the United States. Seminars in Liver Disease 23: 217-226.
- 15. Cullen JM, Miller RT (2006). The role of pathology in the identification of druginduced hepatic toxicity. Expert Opinion on Drug Metabolism and Toxicology 2: 241-247.
- 16. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH (2001). Complementary and alternative medicine in chronic liver disease. Hepatology 34: 595-603.
- 17. Saller R, Meier R, Brignoli R (2001). The use of silymarin in the treatment of liver diseases. Drugs 61: 2035–2063.
- 18. Flora K, Hahn M, Rosen H, Benner K (1998). Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 93: 139-143.
- 19. Pascual C, Gonz R, Armesto J, Muriel P (1993). Effect of silymarin and silybinin on oxygen radicals. Drug Development Research 29: 73-77.
- 20. Mourelle M, Muriel P, Favari L, Franco T (1989). Prevention of CCl4 induced liver cirrhosis by silymarin. Fundamental and Clinical Pharmacology 3: 183-191.
- 21. Pradhan SC, Girish C (2006). Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian Journal of Medical Research 124: 491-504.
- 22. Mukerjee AB, Dasgupta M (1970). Treatment of viral hepatitis by an indigenous drug Liv.52. Indian Practitioner 6: 357-366.
- 23. Charak Samhita, Vimanasthan (1981). Chapter I. Translated by P.V. Sharma, Chaukhamba Orientalia Publishers, Varanasi.
- 24. Radwan MA (2000). Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. Journal of Pharmacy and Pharmacology 52: 665-669.
- 25. Manoukian AV, Carson JL (1996). Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Safety 15: 64-71.
- 26. McGettigan MP, Henry D (2000). Current problems with non-specific COX inhibitors. Current Pharmaceutical Design 6: 1693-1724.
- 27. Rabinovitz M, Van Thiel DH (1992). Hepatotoxicity of nonsteroidal anti-inflammatory drugs. The American Journal of Gastroenterology 87: 1696-1704.
- 28. Merlani G, Fox M, Oehen HP, Cathomas G, Renner EL, Fattinger K, Schneemann M, Kullak-Ublick GA (2001). Fatal hepatotoxicity secondary to nimesulide. European Journal of Clinical Pharmacology 57: 321-326.
- 29. Aithal PG, Day CP (1999). The natural history of histologically proved drug induced liver disease. Gut 44: 731-735.
- 30. Purcell P, Henry D, Melville G (1991). Diclofenac hepatitis. Gut 32: 1381-1385.
- 31. Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995). Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology 22: 820-827.
- 32. Tang W, Stearns RA, Wang RW, Chiu SH, Baillie TA (1999). Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chemical Research in Toxicology 12: 192-199.
- 33. Garcia Rodriguez LA, Perez-Gutthann S, Walker AM, Lueck L (1992). The role of nonsteroidal anti-inflammatory drugs in acute liver injury. British Medical Journal 305: 865–868.
- 34. Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD (2001). Cyclooxygenase selectivity of non-steroidal antiinflammatory drugs in humans: ex vivo evaluation. European Journal of Pharmacology 426: 95-103.
- 35. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F (2001). Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33: 123-130.
- 36. Goldkind L, Laine L (2006). A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiology and Drug Safety 15: 213-200.
- 37. Boardman PL, Hart FD (1967). Side-effects of indomethacin. Annals of the Rheumatic Diseases 26: 127-132.
- 38. Zhou Z, Sun X, Kang JY (2002). Metallothionein protection against alcoholic liver injury through inhibition of oxidative stress. Experimental Biology and Medicine 227: 214-222.
- 39. Kadiiska MB, Gladen BC, Baird DD, Dikalova AE, Sohal RS, Hatch GE, Jones DP, Mason RP, Barrett JC (2000). Biomarkers of oxidative stress study: are plasma antioxidants markers of CCl4 poisoning? Free Radical Biology and Medicine 28: 838- 845.
- 40. Hernandez-Munoz R, Diaz-Munoz M, Suarez J, Chagoya de Sanchez V (1990). Adenosine partially prevents cirrhosis induced by carbon tetrachloride in rats. Hepatology 12: 242-248.
- 41. Whitcomb DC (1994). Acetaminophen poisoning and liver function. The New England Journal of Medicine 331: 1311-1312.
- 42. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B (1994). Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology 19: 1141-1148.
- 43. Anandan R, Rekha DR, Devaki T (1999). Protective effect of Picrorhiza kurroa on mitochondrial glutathione antioxidant system in D-galactosamine-induced hepatitis in rats. Current Science 76: 1543-1545.
- 44. Ravikumar V, Shivashangari KS, Devaki T (2005). Hepatoprotective activity of Tridax procumbens against d-galactosamine/lipopolysaccharide-induced hepatitis in rats. Journal of Ethnopharmacology 101: 55-60.
- 45. Schuppan D, Jia JD, Brinkhaus B, Hahn EG (1999). Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104.